Subject(s)
Counseling/methods , Factor X Deficiency/diagnosis , Adult , Female , Humans , Pregnancy , Retrospective StudiesABSTRACT
BACKGROUND: BK viral nephropathy is an increasingly recognized cause of early allograft loss in kidney transplantation. This study aimed to determine whether a sirolimus (Sir)-based calcineurin inhibitor-sparing regimen is associated with a lower incidence of BK viremia. METHODS: This was a single-center retrospective study. Patients were either on tacrolimus (Tac)-based or on Sir-based immunosuppression. Conversion from Tac to Sir occurred at or after 3 months if patients were <62 years of age, had calculated panel reactive antibodies of <20%, and did not have acute early rejection. RESULTS: Incidence of clinically significant BK viremia was 17.9% in the Tac group and 4.3% in the Sir group. Cox regression multivariate analysis showed that male gender (hazard ratio [HR] = 2.87) and switch to Sir (HR = 0.333) impacted the incidence of BK viremia. Kaplan-Meier analysis showed a higher BK-free survival in the Sir group. A trend was seen toward shorter time to resolution of BK viremia and lower peak viremia in the Sir group. Patients on Sir had a higher estimated glomerular filtration rate at each time point; 34% of patients discontinued Sir because of side effects. CONCLUSION: Conversion to Sir-based maintenance immunosuppression at or about 3 months after kidney transplantation correlates with a lower incidence of BK viremia.
Subject(s)
BK Virus/drug effects , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/adverse effects , Polyomavirus Infections/prevention & control , Sirolimus/therapeutic use , Tacrolimus/therapeutic use , Tumor Virus Infections/prevention & control , Adult , Aged , Female , Humans , Immunosuppression Therapy , Incidence , Male , Middle Aged , Polyomavirus Infections/drug therapy , Retrospective Studies , Transplant Recipients , Tumor Virus Infections/drug therapy , ViremiaSubject(s)
Angina, Unstable/prevention & control , Angina, Unstable/rehabilitation , Myocardial Infarction/prevention & control , Myocardial Infarction/rehabilitation , Cardiovascular Diseases/prevention & control , Depression/prevention & control , Humans , Hyperlipidemias/prevention & control , Obesity/prevention & control , Risk Assessment , Smoking Prevention , Stress, Psychological/prevention & controlSubject(s)
Humans , Angina, Unstable/prevention & control , Angina, Unstable/rehabilitation , Myocardial Infarction/prevention & control , Myocardial Infarction/rehabilitation , Cardiovascular Diseases/prevention & control , Depression/prevention & control , Hyperlipidemias/prevention & control , Obesity/prevention & control , Risk Assessment , Smoking/prevention & control , Stress, Psychological/prevention & controlABSTRACT
Approximately 30% of all patients listed for a kidney transplant in the United States are on inactive status. The consequences of temporary inactivation and rates of transplantation in this group of patients have not been reported. We undertook a retrospective cohort study at our transplant center examining all patients listed between 2001 and 2007. We examined the rate of inactivation, risk factors, duration, and outcomes including transplantation rates and patient survival while on the waiting list and after transplantation. There were 436 patients included in the analysis; 322 (73.9%) were never inactivated and 114 patients (26.1%) were temporarily inactive. The most common causes for inactivation were cardiovascular and suspected malignancy. Time to reactivation was similar among different causes. Waiting times for transplantation (excluding time of inactivation) was 18.7 ± 0.9 versus 39.9 ± 2.3 months for active compared with temporarily inactive patients (log-rank P < .0001). Sixty-five percent of patients were reactivated within 24 months. Approximately one-third of patients were never reactivated. Patient survival was similar among both groups. Temporary inactivation is an independent risk factor for a prolonged waiting time even if time of inactivation is not accounted for. Effective strategies for monitoring patients temporarily inactive on the waiting list should be developed.
Subject(s)
Kidney Transplantation , Outcome and Process Assessment, Health Care , Tissue and Organ Procurement , Waiting Lists , Adult , Female , Humans , Iowa , Kidney Transplantation/adverse effects , Kidney Transplantation/mortality , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Assessment , Risk Factors , Survival Analysis , Time Factors , Waiting Lists/mortalitySubject(s)
Counseling , Factor X Deficiency/therapy , Pregnancy Complications, Hematologic/therapy , Adult , Blood Coagulation Factors/therapeutic use , Cesarean Section , Coagulants/therapeutic use , Counseling/methods , Factor X/therapeutic use , Female , Humans , Pregnancy , Pregnancy Complications, Hematologic/blood , Ultrasonography, Prenatal/methodsABSTRACT
No disponible
Subject(s)
Humans , Iatrogenic Disease , Conjunctivitis/chemically induced , Skin Tests/adverse effectsABSTRACT
Multivariable logistic regression is an important method to evaluate risk factors and prognosis in solid organ transplant literature. We aimed to assess the quality of this method in six major transplantation journals. Eleven analytical criteria and four documentation criteria were analyzed for each selected article that used logistic regression. A total of 106 studies (6%) out of 1,701 original articles used logistic regression analyses from January 1, 2005 to January 1, 2006. The analytical criteria and their respective reporting percentage among the six journals were: Linearity (25%); Beta coefficient (48%); Interaction tests (19%); Main estimates (98%); Ovefitting prevention (84%); Goodness-of-fit (3.8%); Multicolinearity (4.7%); Internal validation (3.8%); External validation (8.5%). The documentation criteria were reported as follows: Selection of independent variables (73%); Coding of variables (9%); Fitting procedures (49%); Statistical program (65%). No significant differences were found among different journals or between general versus subspecialty journals with respect to reporting quality. We found that the report of logistic regression is unsatisfactory in transplantation journals. Because our findings may have major consequences for the care of transplant patients and for the design of transplant clinical trials, we recommend a practical solution for the use and reporting of logistic regression in transplantation journals.
Subject(s)
Clinical Trials as Topic/statistics & numerical data , Logistic Models , Organ Transplantation/statistics & numerical data , Publications/statistics & numerical data , Documentation/standards , Humans , Observer Variation , Organ Transplantation/standards , Publications/standardsSubject(s)
Antigens, Dermatophagoides , Complex Mixtures , Conjunctivitis/diagnosis , Conjunctivitis/etiology , Hypersensitivity, Immediate/diagnosis , Rhinitis/diagnosis , Rhinitis/etiology , Skin Tests/adverse effects , Adult , Animals , Antigens, Dermatophagoides/immunology , Complex Mixtures/chemistry , Complex Mixtures/standards , Conjunctivitis/drug therapy , Conjunctivitis/physiopathology , Dermatophagoides pteronyssinus/immunology , Diagnostic Tests, Routine/methods , Diagnostic Tests, Routine/standards , Humans , Hypersensitivity, Immediate/drug therapy , Hypersensitivity, Immediate/physiopathology , Male , Medication Errors/adverse effects , Practice Guidelines as Topic , Rhinitis/drug therapy , Rhinitis/physiopathologySubject(s)
Frontal Lobe/parasitology , Neuroschistosomiasis/pathology , Neuroschistosomiasis/parasitology , Parietal Lobe/parasitology , Schistosoma mansoni/isolation & purification , Aged , Animals , Biopsy, Needle , Fluorescent Antibody Technique, Direct , Frontal Lobe/pathology , Frontal Lobe/surgery , Humans , Immunoglobulin G/immunology , Magnetic Resonance Imaging , Male , Neuroschistosomiasis/surgery , Parietal Lobe/pathology , Parietal Lobe/surgery , Radiosurgery/methods , Schistosoma mansoni/immunology , Spinal Cord/parasitology , Spinal Cord/pathologyABSTRACT
Cardiopulmonary bypass is frequently associated with excessive blood loss. Platelet dysfunction is the main cause of non-surgical bleeding after open-heart surgery. We randomized 65 patients in a double-blind fashion to receive tranexamic acid or placebo in order to determine whether antifibrinolytic therapy reduces chest tube drainage. The tranexamic acid group received an intravenous loading dose of 10 mg/kg, before the skin incision, followed by a continuous infusion of 1 mg kg(-1) h(-1) for 5 h. The placebo group received a bolus of normal saline solution and continuous infusion of normal saline for 5 h. Postoperative bleeding and fibrinolytic activity were assessed. Hematologic data, convulsive seizures, allogeneic transfusion, occurrence of myocardial infarction, mortality, allergic reactions, postoperative renal insufficiency, and reopening rate were also evaluated. The placebo group had a greater postoperative blood loss (median (25th to 75th percentile) 12 h after surgery (540 (350-750) vs 300 (250-455) mL, P = 0.001). The placebo group also had greater blood loss 24 h after surgery (800 (520-1050) vs 500 (415-725) mL, P = 0.008). There was a significant increase in plasma D-dimer levels after coronary artery bypass grafting only in patients of the placebo group, whereas no significant changes were observed in the group treated with tranexamic acid. The D-dimer levels were 1057 (1025-1100) microg/L in the placebo group and 520 (435-837) microg/L in the tranexamic acid group (P = 0.01). We conclude that tranexamic acid effectively reduces postoperative bleeding and fibrinolysis in patients undergoing first-time coronary artery bypass grafting compared to placebo.
Subject(s)
Antifibrinolytic Agents/therapeutic use , Cardiopulmonary Bypass/adverse effects , Coronary Artery Bypass/adverse effects , Fibrinolysis/drug effects , Postoperative Hemorrhage/prevention & control , Tranexamic Acid/therapeutic use , Cardiopulmonary Bypass/methods , Coronary Artery Bypass/methods , Double-Blind Method , Female , Humans , Male , Middle Aged , Prospective StudiesABSTRACT
Cardiopulmonary bypass is frequently associated with excessive blood loss. Platelet dysfunction is the main cause of non-surgical bleeding after open-heart surgery. We randomized 65 patients in a double-blind fashion to receive tranexamic acid or placebo in order to determine whether antifibrinolytic therapy reduces chest tube drainage. The tranexamic acid group received an intravenous loading dose of 10 mg/kg, before the skin incision, followed by a continuous infusion of 1 mg kg-1 h-1 for 5 h. The placebo group received a bolus of normal saline solution and continuous infusion of normal saline for 5 h. Postoperative bleeding and fibrinolytic activity were assessed. Hematologic data, convulsive seizures, allogeneic transfusion, occurrence of myocardial infarction, mortality, allergic reactions, postoperative renal insufficiency, and reopening rate were also evaluated. The placebo group had a greater postoperative blood loss (median (25th to 75th percentile) 12 h after surgery (540 (350-750) vs 300 (250-455) mL, P = 0.001). The placebo group also had greater blood loss 24 h after surgery (800 (520-1050) vs 500 (415-725) mL, P = 0.008). There was a significant increase in plasma D-dimer levels after coronary artery bypass grafting only in patients of the placebo group, whereas no significant changes were observed in the group treated with tranexamic acid. The D-dimer levels were 1057 (1025-1100) æg/L in the placebo group and 520 (435-837) æg/L in the tranexamic acid group (P = 0.01). We conclude that tranexamic acid effectively reduces postoperative bleeding and fibrinolysis in patients undergoing first-time coronary artery bypass grafting compared to placebo.
Subject(s)
Humans , Male , Female , Antifibrinolytic Agents/therapeutic use , Cardiopulmonary Bypass/adverse effects , Coronary Artery Bypass/adverse effects , Fibrinolysis/drug effects , Postoperative Hemorrhage/prevention & control , Tranexamic Acid/therapeutic use , Cardiopulmonary Bypass/methods , Coronary Artery Bypass/methods , Double-Blind Method , Prospective StudiesABSTRACT
INTRODUCTION: Nemaline myopathy is a type of congenital myopathy which presents with hypotonia, muscle weakness which is predominantly proximal, lax ligaments, areflexia and skeletal deformities. It is characterized by the presence of intrasarcolemal or intranuclear rods which can be seen with the red color optical microscope using the Gomori technique, and a defect in the Z line of the sarcomere, detected on electron microscopy (EM). PATIENTS AND METHODS: A retrospective study of the cases of nemaline congenital myopathy diagnosed in our hospital between 1984 and 1997. All patients had clinical laboratory analysis (muscle enzymes), and electromyographic and histopathological (muscle biopsy) studies. In 5 cases EM was done. RESULTS: Nine patients, four males and five females were studied. Diagnosis was made during the first year of life in 7 cases (77.7%), and was characterized by hypotonia, severe areflexia and proximal muscle weakness, whilst the remainder were diagnosed in adolescence when they presented with a juvenile form of the disorder, with muscle weakness, amyotrophy and scoliosis. Muscle biopsy showed nemaline bodies in a variable proportion of fibres. Intranuclear rods were not identified in any case. In the 5 cases in which ultrastructural studies were done, alterations were detected in the Z line of the sarcomere. The immunohistochemical profile of the rods was positive for alphaactin. CONCLUSIONS: There are no clinical features which permit distinction from other forms of congenital myopathy, so muscle biopsy is necessary for diagnosis. There is great phenotype and prognostic variety in this disorder.
Subject(s)
Myopathies, Nemaline/pathology , Actins/analysis , Adolescent , Adult , Age of Onset , Biopsy , Child , Child, Preschool , Diagnosis, Differential , Electromyography , Female , Humans , Inclusion Bodies/ultrastructure , Infant , Male , Muscle, Skeletal/pathology , Muscular Diseases/diagnosis , Myopathies, Nemaline/diagnosis , Reflex, Abnormal , Retrospective StudiesABSTRACT
OBJECTIVE: To analyze late clinical evolution after surgical treatment of children, with reparative and reconstructive techniques without annular support. METHODS: We evaluated 21 patients operated upon between 1975 and 1998. Age 4.67+/-3.44 years; 47.6% girls; mitral insufficiency 57.1% (12 cases), stenosis 28.6% (6 cases), and double lesion 14.3% (3 cases). The perfusion 43.10+/-9.50 min, and ischemia time were 29.40+/-10.50 min. The average clinical follow-up in mitral insufficiency was 41.52+/-53.61 months. In the stenosis group (4 patients) was 46.39+/-32.02 months, and in the double lesion group (3 patients), 39.41+/-37.5 months. The echocardiographic follow-up was in mitral insufficiency 37.17+/-39.51 months, stenosis 42.61+/-30.59 months, and in the double lesion 39.41+/-37.51 months. RESULTS: Operative mortality was 9.5% (2 cases). No late deaths occurred. In the group with mitral insufficiency, 10 (83.3%) patients were asymptomatic (p=0.04). The majority with mild reflux (p=0.002). In the follow-up of the stenosis group, all were in functional class I (NYHA); and the mean transvalve gradient varied between 8 and 12 mmHg, average of 10.7 mmHg. In the double lesion group, 1 patient was reoperated at 43 months. No endocarditis or thromboembolism were reported. CONCLUSION: Mitral stenosis repair has worse late results, related to the valve abnormalities and associated lesions. The correction of mitral insufficiency without annular support showed good long-term results.
Subject(s)
Mitral Valve Insufficiency/surgery , Mitral Valve Stenosis/surgery , Mitral Valve/surgery , Adolescent , Child , Child, Preschool , Disease-Free Survival , Female , Follow-Up Studies , Humans , Infant , Male , Mitral Valve/abnormalities , Mitral Valve Insufficiency/congenital , Mitral Valve Stenosis/congenital , Time Factors , Treatment OutcomeABSTRACT
Mitral valve repair may be performed without ring support with advantages related to results and complications. The objective of this study was to analyze the long-term clinical results following surgical repair and reconstruction without the use of rings in cases of congenital mitral lesions in children less than 12 years of age. Twenty-one patients who had undergone surgery during the period from 1975 to 1998 were evaluated. The mean age was 4.6 +/- 3.4 years. Females represented 47.6% of the total. Mitral regurgitation was present in 57.1% (12 patients), stenosis in 28.6% (6 patients), and the mixed lesion group represented 14.3% (3 patients). Perfusion time was 43.1 +/- 9.5 minutes and ischemic time 29.4 +/- 10.5 minutes. Follow-up time was 41.5 +/- 53.6 months for the regurgitation group, 46.3 +/- 32.0 months for the stenosis group, and 39.41 +/- 37.51 months for the mixed lesion group. Echocardiographical follow-up time was 37.17 +/- 39.51 months for the regurgitation group, 42.61 +/- 30.59 months for the stenosis group, and 39.41 +/- 37.51 months for the mixed lesion group. Operative mortality was 9.5% (two cases). There were no late deaths. In the regurgitation group, 10 patients (83.3%) were asymptomatic (p = 0.004). In the echocardiographical follow-up, most of the patients had minimal regurgitation. In the clinical follow-up of the stenosis group all patients were in functional class I (NYHA). The mean transvalvular gradient measured by echocardiography was from 8 to 12 mmHg with a mean gradient of 10.7 mmHg. In the mixed lesion group there was one reoperation at postoperative month 43. There were no cases of endocarditis or thromboembolism. Mitral valve repair in congenital lesions is associated with good late results. The majority of cases in the regurgitation group remain asymptomatic and do not require reoperation. Rings or annular support are not necessary in such cases. Satisfactory repair is more difficult to achieve in cases of mitral stenosis due to valvular abnormalities and the seriousness of the associated lesions.
Subject(s)
Mitral Valve Insufficiency/congenital , Mitral Valve Stenosis/congenital , Mitral Valve/abnormalities , Child , Child, Preschool , Echocardiography , Female , Humans , Infant , Male , Mitral Valve/surgery , Mitral Valve Insufficiency/mortality , Mitral Valve Insufficiency/surgery , Mitral Valve Stenosis/mortality , Mitral Valve Stenosis/surgery , Time FactorsABSTRACT
PURPOSE: To determine the effects of panretinal photocoagulation (PRP) on the levels of cytochrome oxidase (CO), Zif268, synaptophysin, and growth-associated protein 43 (GAP-43) in the primary visual cortex of adult monkeys. METHODS: Ten adult primates underwent unilateral argon laser PRP with instrument settings at 300 to 500 microns spot diameter, 200 to 500 mW power intensity, and 0.1 to 0.2 second duration, causing moderate to severe burns in the peripheral retina. At 20 hours, 12 days, 6 months, and 13 months after laser treatment, the visual cortex was assessed histologically for CO and immunohistochemically for Zif268, synaptophysin, and GAP-43. RESULTS: PRP resulted in transneuronal changes in the relative distributions of CO, Zif268, synaptophysin, and GAP-43 in the primary visual cortex. CO activity was relatively decreased in the lasered eye's ocular dominance columns at 12 days post-PRP, with recovery by 13 months post-PRP. The level of Zif268 was dramatically decreased in the lasered eye's ocular dominance columns at 20 hours post-PRP, with gradual recovery by 13 months post-PRP. Levels of synaptophysin and GAP-43 immunoreactivity were increased in both the lasered and the nonlasered eyes' ocular dominance columns at 6 months post-PRP. CONCLUSION: PRP treatment results in metabolic activity changes in the visual cortex of the adult monkey. These changes are followed chronologically by spatial redistribution of synaptophysin and GAP-43, neurochemicals known to play a role in cortical plasticity. This study demonstrates, for the first time, that PRP as used in the treatment of diabetic retinopathy results in a redistribution of neurochemicals in the adult monkey visual cortex. Such changes may help explain the anomalous visual functional loss often reported by patients after PRP.
Subject(s)
Laser Coagulation , Nerve Tissue Proteins/metabolism , Retina/surgery , Visual Cortex/metabolism , Animals , DNA-Binding Proteins/metabolism , Electron Transport Complex IV/metabolism , Female , GAP-43 Protein/metabolism , Immunoenzyme Techniques , Macaca fascicularis , Macaca mulatta , Male , Neuronal Plasticity , Neurons/metabolism , Synaptophysin/metabolism , Transcription Factors/metabolismABSTRACT
INTRODUÇÇO: A correçäo cirúrgica da estenose aórtica resulta em reduçäo significativa do gradiente pressórico transvalvar, sendo acompanhada por regressäo da hipertrofia ventricular esquerda(HVE). A intensidade e a rapidez dessa regressäo tem sido objeto de avaliaçöes. A associaçäo de valvoplastia aórtica e regressäo imediata da HVE é relatada em poucos estudos. MÉTODOS: Foram estudados, prospectivamente, 11 pacientes submetidos à valvoplastia em estenose aórtica, utilizando-se ecocardiografia imediatamente antes da cirurgia e no período pós-operatório precoce (6,1 + ou - 0,9 dias). RESULTADOS: A espessura septal variou de 12,10 + ou - 1,66mm para 11,36 + ou - 1,12mm (reduçäo de 6,1 por cento) (NS) enquanto a espessura parietal variou 4,4 por cento (de 11,70 + ou - 1,41 mm para 11,18 + ou - 1,16mm) (NS). A fraçäo de ejeçöo apresentou uma variaçäo de 62,02 + ou - 18,59 por cento para 62,50 + ou - 11,74 por cento (NS). A massa ventricular esquerda variou em 6,7 por cento ( de 277,65 + ou - 114,80 g passou para 258,93 + ou - 92,38 g) (NS). O gradiente transvalvular médio regrediu de 53,6 + ou -10,3 mmHg para 23,0 + ou - 9,1mmHg, ou seja, 57 por cento (p<0.001). CONCLUSÕES: A valvoplastia alivia o gradiente pressórico aórtico satisfatoriamente e a regressäo da HVE tende a se iniciar logo após, porém ainda näo é significativa no período pós-operatório imediato
Subject(s)
Humans , Middle Aged , Male , Female , Aortic Valve Stenosis/surgery , Heart Valve Prosthesis , Hypertrophy, Left Ventricular/surgery , Postoperative Period , Prospective StudiesABSTRACT
More than 500,000 new medical articles are published every year and available time to keep updated is scarcer every day. Nowadays, the task of selecting useful, consistent, and relevant information for clinicians is a priority in many major medical journals. This review has the aim of gathering the results of the most important findings in clinical medicine in the last few years. It is focused on results from randomized clinical trials and well-designed observational research. Findings were included preferentially if they showed solid results, and we avoided as much as possible including only preliminary data, or results that included only non-clinical outcomes. Some of the most relevant findings reported here include the significant benefit of statins in patients with coronary artery disease even with mean cholesterol level. It also provides a substantial review of the most significant trials assessing the effectiveness of IIb/IIIa receptor blockers. In gastroenterology many advances have been made in the H. pylori eradication, and the finding that the cure of H. pylori infection may be followed by gastroesophageal reflux disease. Some new antivirals have shown encouraging results in patients with chronic hepatitis. In the infectious disease arena, the late breaking trials in anti-retroviral disease are discussed, as well as the new trends regarding antibiotic resistance. This review approaches also the role of leukotriene modifiers in the treatment of asthma and discusses the benefit of using methylprednisolone in patients with adult respiratory distress syndrome, among many other advances in internal medicine.
Subject(s)
Internal Medicine/trends , Acquired Immunodeficiency Syndrome , Behavior , Cardiology/trends , Communicable Diseases , Gastroenterology/trends , HIV , Hematology/trends , Humans , Lung Diseases, Obstructive , Medical Oncology/trends , Nephrology/trends , Rheumatology/trendsABSTRACT
Dedifferentiation, a change in the histologic character and clinical behavior of a tumor to a more immature and aggressive one, occurs in approximately 11% of all chondrosarcomas. The original lesion is usually a low-grade chondrosarcoma. Clear cell chondrosarcoma is a rare cartilaginous tumor of low-grade malignancy with a preference for the ends of long bones. It is usually curable by resection. Recurrence commonly follows inadequate surgery, and metastases to lung, brain, and bones can develop. However, dedifferentiation has not yet been described in association with clear cell chondrosarcoma. Three patients are described who were initially diagnosed as having clear cell chondrosarcoma of the femur. Two were treated with en bloc resection for a clear cell chondrosarcoma. One of these had an undifferentiated sarcoma in a local recurrence after 6 years. In the second, metastasis of the clear cell chondrosarcoma developed 5(1/2) years after surgery; autopsy revealed undifferentiated sarcoma in the lung, heart, and lumbar spine. The third patient had dedifferentiated clear cell chondrosarcoma at the time of resection following the biopsy diagnosis of clear cell chondrosarcoma. All three died with metastatic disease. These three patients represent three different manifestations of dedifferentiation-at initial diagnosis, at recurrence, and at metastasis. To our knowledge, this is the first description of dedifferentiation occurring in clear cell chondrosarcoma.